SBFM
Sunshine Biopharma, Inc.NASDAQHealthcare$1.04+11.54%ClosedMarket Cap: $5.1M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.21
P/S
0.16
EV/EBITDA
0.61
DCF Value
$-483.53
FCF Yield
-93.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
33.8%
Operating Margin
-17.2%
Net Margin
-16.5%
ROE
-25.0%
ROA
-185.2%
ROIC
193.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| FY 2025 | $36.3M | 33.8% | $-6.2M | $-6.0M | $-1.44 | — |
| Q3 2025 | $9.4M | 32.6% | $-1.1M | $-883.8K | $-0.19 | — |
| Q2 2025 | $9.4M | 36.4% | $-2.1M | $-1.8M | $-7.80 | — |
| Q1 2025 | $8.9M | 30.7% | $-1.3M | $-1.2M | $-0.44 | — |
| Q4 2024 | $9.6M | 32.2% | $-2.0M | $-2.2M | $-0.84 | — |
| FY 2024 | $34.9M | 30.6% | $-5.8M | $-5.1M | $-7.32 | — |
| Q3 2024 | $8.4M | 34.0% | $-1.1M | $-1.2M | $-0.94 | — |
| Q2 2024 | $9.3M | 24.8% | $-1.3M | $-494.0K | $-9.94 | — |
| Q1 2024 | $7.5M | 30.7% | $-1.4M | $-1.3M | $-40.04 | — |
| Q4 2023 | $7.7M | 33.4% | $-1.2M | $-1.3M | $-104.69 | — |
| FY 2023 | $24.1M | 34.6% | $-4.8M | $-4.5M | $-351.36 | — |
| Q3 2023 | $6.0M | 33.4% | $-779.0K | $-651.0K | $-50.72 | — |